PERNIX THERAPEUTICS, LLC – Trademark Portfolio
Entity Type: 16
PERNIX THERAPEUTICS, LLC holds 30 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 28 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include CEDAX. The owner is based in GONZALES, LA.
P.O.BOX 40
GONZALES, LA 70707
Showing of trademarks Trademarks
Trademark Classifications
PERNIX THERAPEUTICS, LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does PERNIX THERAPEUTICS, LLC have?
PERNIX THERAPEUTICS, LLC has 30 U.S. trademarks filed with the USPTO. Of these, 1 registered, 13 abandoned, 16 cancelled.
What trademark classes does PERNIX THERAPEUTICS, LLC file in?
PERNIX THERAPEUTICS, LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are PERNIX THERAPEUTICS, LLC's most well-known trademarks?
PERNIX THERAPEUTICS, LLC's registered trademark portfolio includes well-known marks such as CEDAX. These are among 1 currently registered trademark in the portfolio.
What is PERNIX THERAPEUTICS, LLC's trademark registration success rate?
PERNIX THERAPEUTICS, LLC has a 3% trademark registration rate, with 1 out of 30 resolved applications resulting in successful registration. Currently, 0 applications are pending review.